Primary colonic extrauterine endometrial stromal sarcoma: A case and review of the literature

Kuhali Kundua, Theresa Kuhnab,⁎, Adrian Kohutac, Charles Staleyb, Krisztina Hanleyc, Namita Khannad

a Emory University School of Medicine, Department of Gynecology and Obstetrics, Atlanta, GA, United States
b Emory University School of Medicine, Department of Surgery, Division of Surgical Oncology, Atlanta, GA, United States
c Emory University School of Medicine, Department of Pathology, Atlanta, GA, United States
d Emory University School of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Atlanta, GA, United States

1. Background

Endometrial stromal sarcoma (ESS) is an uncommon uterine mesenchymal neoplasm, accounting for < 10% of uterine sarcomas and < 1% of all primary malignant tumors of the uterus. The 2014 WHO classification of tumors of the female reproductive organs subclassifies endometrial stromal tumors into 4 subtypes based on clinical and pathological features: benign endometrial stromal nodule (ESN), low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and undifferentiated uterine sarcoma (UUS). ESN and LG-ESS are distinguished on the bases of myoinvasive growth pattern and lymphovascular invasion. ESN are well-circumscribed, which distinguishes them from LG-ESS. Tongue-like myoinvasion of at least 3 mm, in three separate areas, is the diagnostic criteria widely used to establish the diagnosis of LG-ESS. If vascular invasion is present, the diagnosis of LG-ESS is straightforward.

The most common genetic alteration identified in ESN is t(7;17) (p15;g21), resulting in the fusion of the JAZF1/SUZ12 genes, which is also present in about 48% of LG-ESS (Conklin and Longacre, 2014). The diagnosis of endometrial stromal tumors on hysterectomy specimen is not difficult, but requires extensive tissue sampling, immunohistochemical workup, or even molecular studies. However, a biopsy sample lacking endometrial glands may be interpreted as ESN or LG-ESS, as there are no histologic features or ancillary techniques that distinguish them.

Primary extrauterine endometrial stromal sarcomas can arise in the setting of endometriosis. While they are very rare, they have been reported in the ovary, bowel, abdomen, peritoneum, pelvis, and vagina. There are only a few reported cases of endometrial stromal sarcomas arising from the gastrointestinal tract, which are highlighted in Table 1. These tumors tend to be low-grade and indolent in nature, but since they often present at advanced stage, disease recurrence is common (Baiocchi et al., 1990; Yantiss et al., 2000; Bosincu et al., 2001; Mourra et al., 2001; Cho et al., 2002; Kovac et al., 2005; Chen et al., 2007; Ayuso et al., 2013; Wang et al., 2015; Son et al., 2015). This paper will present a patient diagnosed with LG-ESS arising from endometriosis of the sigmoid colon and highlight how molecular technology can be used in the diagnosis of endometrial stromal sarcoma on a biopsy specimen.

2. Case study

The patient is a 37-year-old Caucasian female, G2P0-0-0-2, who presented with abdominal pain and bright red blood per rectum with no other symptoms or significant medical, surgical and gynecologic history. A colonoscopy showed a 4.0 × 2.6 cm mass in her sigmoid colon. As part of her evaluation, she had CT scan and MRI of the chest, abdomen, and pelvis. There were no abnormalities noted in the uterus and fallopian tubes. Both ovaries had simple cysts measuring up to 2.5 cm. An ill-defined lesion in the subcapsular region of the hepatic dome with possible extension through the diaphragm into the lung base was identified.

Based on the suspicion for colon carcinoma, a biopsy of the colonic mass was performed. Pathology showed endometrial stromal proliferation without endometrial glands, involving full thickness of the colonic mucosa (Fig. 1, image A-C). The differential diagnosis based on this biopsy included an under-sampled focus of endometriosis or LG-ESS. Due to inconclusive histologic results and imaging findings concerning for a neoplastic process, further workup was performed. A CT-guided biopsy of the liver lesion was attempted but was unsuccessful due to the location of the lesion. Endometrial biopsy showed proliferative endometrium with no evidence of a neoplasia. Given that up to 50% of LG-ESS show the characteristic t(7;17)(p15;g21) translocation, the laboratory performed the Archer® FusionPlex® Sarcoma panel on the biopsy specimen. This test identified the presence of JAZF1/SUZ12 fusion gene, which confirmed the diagnosis of LG-ESS.

The patient subsequently underwent an exploratory laparotomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, rectosigmoid colectomy with primary anastomosis, resection of right...
<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Age</th>
<th>History of Gyn Surgery/History of Endometriosis</th>
<th>Symptoms at Presentation</th>
<th>Involving Colon Site</th>
<th>Gross findings, colon</th>
<th>Presence of endometriosis</th>
<th>Dissemination</th>
<th>Surgical Management</th>
<th>Adjuvant Treatment</th>
<th>Follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baiocchi 1990</td>
<td>38</td>
<td>TAH, BSO for endometriosis</td>
<td>Abdominal pain and pressure</td>
<td>Ascending and transverse colon, terminal ileum</td>
<td>A large multilocular mass involving the transverse, ascending colon, and the terminal ileum</td>
<td>Ovary and colon</td>
<td>Local (mesentery, pelvis, and falciform ligaments)</td>
<td>Partial ileal resection, resection of the transverse and ascending colon</td>
<td>Etoposide, bleomycin, and cisplatin × 3 cycles followed by progesterone agent</td>
<td>NED 16 months</td>
</tr>
<tr>
<td>Baiocchi 1990</td>
<td>50</td>
<td>TAH, RSO for endometriosis</td>
<td>Abdominal pain</td>
<td>Transverse colon, junction of the descending and sigmoid colon</td>
<td>A large grapelike tumor, with individual nodular areas 2 × 2.5 cm</td>
<td>Ovary</td>
<td>Omentum</td>
<td>LSO, radical omentectomy</td>
<td>Megace</td>
<td>NED</td>
</tr>
<tr>
<td>Yantiss 2000</td>
<td>63</td>
<td>None/No</td>
<td>Change in bowel habits</td>
<td>Rectum</td>
<td>2 cm polypoid mass</td>
<td>NA</td>
<td>NA</td>
<td>Partial colectomy</td>
<td>RT</td>
<td>Recurrent 3 years</td>
</tr>
<tr>
<td>Bostincu 2001</td>
<td>42</td>
<td>None/Yes</td>
<td>Fever and abdominal pain</td>
<td>Rectum</td>
<td>Large polypoid and ulcerated pelvic mass with transmural infiltration into the rectum</td>
<td>Adventitial rectal layer</td>
<td>Local (uterine serosa, parametria, peritoneal lymphatics)</td>
<td>TAH, BSO, omentectomy, colorectal resection</td>
<td>Adriamycin and cyclophosphomide × 4 cycles</td>
<td>NED 20 months</td>
</tr>
<tr>
<td>Moura 2001</td>
<td>61</td>
<td>None/No</td>
<td>Epigastric pain</td>
<td>Rectosigmoid colon</td>
<td>A 2.7 cm polypoid mass with stenosis of the lumen involving all layers of the rectal wall</td>
<td>Posterior wall of right broad ligament</td>
<td>None</td>
<td>Resection of rectosigmoid dilation &amp; Garettage</td>
<td>None</td>
<td>NED 30 months</td>
</tr>
<tr>
<td>Cho 2002</td>
<td>48</td>
<td>TAH for uterine fibroids, and LSO for endometriosis</td>
<td>Tenesmus</td>
<td>Sigmoid colon</td>
<td>Multinodular masses of 1 to 3 cm involving the whole layer of the intestine and extending to the urinary bladder and ureter</td>
<td>Left ovary and sigmoid colon</td>
<td>None</td>
<td>Resection of rectosigmoid and regional lymph node dissection</td>
<td>None</td>
<td>NED 4 months</td>
</tr>
<tr>
<td>Kowac 2005</td>
<td>46</td>
<td>TAH, RSO for uterine fibroids/Yes</td>
<td>Stenosing process</td>
<td>Rectosigmoid colon</td>
<td>6 cm mass</td>
<td>Rectosigmoid colon</td>
<td>Omentum and left ovary</td>
<td>Oophorectomy, omentectomy, and resection of colon</td>
<td>None</td>
<td>NED 11 months</td>
</tr>
<tr>
<td>Chen 2007</td>
<td>42</td>
<td>None/No</td>
<td>Rectal bleeding and tenesmus</td>
<td>Sigmoid colon</td>
<td>Multiple 1 to 3 cm nodular masses involving mucosa and periocolic fat</td>
<td>Sigmoid colon</td>
<td>Omentum and left adnexa</td>
<td>TAH, BSO, resection of rectosigmoid</td>
<td>None</td>
<td>NED 1 year</td>
</tr>
<tr>
<td>Ayuso 2013</td>
<td>80</td>
<td>TAH, BSO/Yes</td>
<td>Rectal bleeding and chronic rectal discharge</td>
<td>Sigmoid colon</td>
<td>5 cm mass involving mucosa, muscularis, and peritoneum</td>
<td>None</td>
<td>Pelvic side wall</td>
<td>Laparoscopic lower anterior colon resection</td>
<td>Megace</td>
<td>NED 4 years</td>
</tr>
<tr>
<td>Wang 2014</td>
<td>40</td>
<td>TAH for uterine fibroid and right ovarian cystectomy/No</td>
<td>Change in bowel habits and rectal bleeding</td>
<td>Rectum</td>
<td>Nodular masses 1 to 3 cm scattered in the intestinal walls and mesentery</td>
<td>Colon</td>
<td>Mesentery and extensive intra-abdominal metastases</td>
<td>Unresectable, palliative transverse omentectomy to relieve stenosis and intraoperative peritoneal chemotherapy</td>
<td>NA</td>
<td>DOD 18 months</td>
</tr>
<tr>
<td>Son 2015</td>
<td>52</td>
<td>None/No</td>
<td>Constipation and hematochezia</td>
<td>Sigmoid colon</td>
<td>Polypoid 3.8 × 2.5 transmural mass</td>
<td>None</td>
<td>Bilateral ovaries with endometrial stromal nodules</td>
<td>TAH, BSO, rectosigmoid resection, omentectomy, resection of diaphragmatic mass, resection of liver lesion</td>
<td>Megace</td>
<td>POD at 3 months, switched to Letrozole, now NED 2 years</td>
</tr>
<tr>
<td>Our case</td>
<td>37</td>
<td>None/No</td>
<td>Rectal bleeding</td>
<td>Sigmoid colon</td>
<td>6 cm multilobulated sigmoid mass</td>
<td>Right ovary and liver lesion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ESS, extrauterine endometroid stromal sarcoma; TAH, total abdominal hysterectomy; TLH, total laparoscopic hysterectomy; BSO, bilateral salpingo-oophorectomy; LSO, left salpingo-oophorectomy; RSO, right salpingo-oophorectomy; RT, radiotherapy; NED, no evidence of disease; DOD, death of disease; POD, progression of disease; NA, not available.
diaphragmatic mass, segmental resection of the right lobe of the liver, and omentectomy. Intra-abdominal findings were more extensive than expected. The patient was found to have a 6 cm sigmoid colon mass, a 6 cm right diaphragm lesion, and multiple omental nodules. All gross disease was resected. Her postoperative course was unremarkable, and she was discharged home one week postoperatively.

Histologic examination of the specimens showed the characteristic features of LG-ESS, with extensive perineural and vascular invasion (Fig. 1, image D). The sigmoid colon lesion was 5.8 cm in its largest dimension, and there was transmural involvement by LG-ESS. Metastatic LG-ESS was evident in the omentum and diaphragm. Lymph nodes, uterus, and the adnexal structures were all negative. She had an endometriotic cyst in her ovary. The tumor was strongly positive for ER, PR, and CD 10.

Given her final diagnosis and that the tumor was strongly positive for estrogen and progesterone receptors, she was started on megestrol acetate as adjuvant therapy and counseled on continued surveillance for recurrence. The patient’s disease progressed on Megace, with an increasing liver lesion noted on surveillance CT three months after surgery, and was switched to Letrozole, which she remains stable on currently.

3. Discussion

LG-ESS arising from primary extrauterine sites is uncommon. There are 11 cases reported of LG-ESS arising in the colon and their findings are summarized in Table 1 (Baiocchi et al., 1990; Wang et al., 2015). Our patient’s case is similar to the ones reported, with the exception that she presented with widespread metastatic disease at the time of diagnosis.

It is known that LG-ESS can occur in the setting of endometriosis. Our patient did not have a known clinical history of endometriosis, but it was histologically confirmed in the ovary. LG-ESS is rare but is the most common mesenchymal malignancy arising from endometriosis. Yantiss et al. (2000) reported the largest case series of primary malignancies arising from gastrointestinal endometriosis. They identified a total of 14 cases, which included 8 cases of endometrioid adenocarcinomas, 4 cases of a Mullerian adenosarcoma, 1 case of a borderline endometrioid tumor, and 1 case of an LG-ESS arising in the colon, seen in Table 1.

The largest published series of LG-ESS cases is a report of 63 cases from MD Anderson Cancer Center by Massand et al. They report that LG-ESS is commonly associated with endometriosis, and that given its indolent nature, long-term follow up is recommended for late recurrences. Endometriosis was noted in 30 of the 63 cases, and close to 25% of cases had an initial pathologic diagnosis other than LG-ESS, including sex cord stromal tumor, gastrointestinal stromal tumor, and leiomyosarcoma. Only 50% of the tumors were initially diagnosed accurately. Of the 53 patients that were followed, 33 patients had recurrent disease, and 9 patients died from disease. There were no clinical or pathological characteristics predictive of poor outcome upon review of the patients who died (Masand et al., 1990).

The diagnosis of LG-ESS can be difficult with limited tissue sample for two reasons. First, the histologic features of malignancy in LG-ESS cannot be fully evaluated on a biopsy sample. Secondly, LG-ESS arising from extrauterine sites often mimics other more common primary mesenchymal tumors, which requires further studies. LG-ESS is diffusely positive in GIST and strongly positive for ER, PR, and CD 10 (Conklin and Longacre, 2014; Ladwig and Garg, 2016; Masand, 2018; McCluggage et al., 2001). A panel of immunohistochemical stains is recommended when differentiating stromal neoplasms from cellular leiomyomas or leiomyosarcoma (NCCN). Gastrointestinal stromal tumor (GIST) and ESS will stain for CD 10 and desmin, but h-caldesmon and SMMS-1 will be positive in GIST and negative in ESS (Masand, 2018). Gastrointestinal stromal tumor (GIST) and ESS have overlapping staining profile, as they both stain for CD10, desmin and smooth muscle actin (SMA), GIST is positive for c-kit (CD117) and DOG-1, while LG-ESS is negative.

It is imperative to correctly classify ESS based on the 2014 WHO Classification because of the implication this has for treatment options and prognosis. Endometrial stromal tumors are a genetically heterogeneous group of tumors that harbor recurrent chromosomal translocations, producing specific gene arrangements. There are many gene
fusions reported for ESN and ESS including PHF1-JAZF1 t(6;7)(p21; p15), EPC1-PHF1 t(6;10;10)(p21;q22;p11.2) and JAZF1-SUZ12 t(7;17) (p15;q21). The JAZF1-SUZ12 translocation, discussed above, is the most common genetic abnormality occurring in 65% of ESNs and up to 48% of LG-ESSs (Conklin and Longacre, 2014). This translocation is specific for LG-ESS and is not present in other uterine mesenchymal neoplasms. Knowing this, we were able to identify the translocation diagnosing LG-ESS on our patient’s limited tissue sample, and surgical treatment was planned.

Given the rarity of these tumors in extraterine sites, evidence-based data is limited to help guide treatment decisions. Cytoreductive surgery is generally considered the treatment for ESS. ESS has a tendency to metastasize widely; despite this, most patients with ESS have prolonged disease-free intervals with late recurrences (Masand et al., 2013). The value of adjuvant therapy is controversial, with no prospective studies showing a survival advantage. LG-ESS tumors tend to be hormone receptor positive, and hormone therapy can be considered to lower the risk of recurrence. Per the NCCN guidelines for LG-ESS of the uterus, aromatase inhibitors are recommended and Megace is also an option (NCCN). Our patient was started on Megace because previous literature has shown success with this treatment in extraterine cases (Baiochi et al., 1990; Ayuso et al., 2013). When she progressed, she was switched to Letrozole with no evidence for now two years after surgery. This highlights the importance of this treatment, as no other extra uterine cases reported have used aromatase inhibitors. HG-ESS, which are negative for ER and PR, do not seem to respond to hormonal therapy and show poor clinical prognosis. Therefore, distinction of LG-ESS from HG-ESS is crucial (Ladwig and Garg, 2016; Oliva et al., 2002). Overall, lifelong surveillance is necessary, as prognostic predictors of ESS remain unclear and there is a risk of late recurrence. The NCCN guidelines recommend physical exam every three to four months for the two to three years and after that one to two times per year. As well a CT scan of the chest, abdomen and pelvis every three to six months for the first three years, then every six to 12 months for years four and five and once a year or every other year for years six through 10 and is to be determined by the individual physician based on tumor characteristics (NCCN).

Extrauterine LG-ESS poses a diagnostic challenge, as patients often present with non-specific or GI symptoms that can be misleading. Furthermore, imaging findings may suggest malignancy due to obstruction, mass effect, and adhesions. Tissue sample is often limited. The diagnosis of extrauterine LG-ESS should only be made when benign entities, like endometriosis, or when morphologic mimickers are excluded via ancillary studies. Molecular studies, if available, may be valuable in this setting, as they can easily be performed on limited tissue. Furthermore, the identification of specific translocations is not only helpful for confirming the diagnosis, but also for future targeted therapies.

4. Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Declaration of Competing Interest

The authors declared that there is no conflict of interest.

References